HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clariant TEA extension request

This article was originally published in The Rose Sheet

Executive Summary

Piroctone olamine manufacturer Clariant seeks 90-day extension to "assemble a comprehensive submission" to FDA on the safety and efficacy of the anti-dandruff ingredient. Firm requests original deadline of May 18 be pushed back to Aug. 16, Washington, D.C. law firm Keller and Heckman says in letter to FDA filed April 16 on behalf of Clariant. Agency issued a call for safety and efficacy data on piroctone olamine as a single active dandruff control ingredient in February to determine if it is eligible for monograph status (1"The Rose Sheet" Feb. 23, 2004, p. 10). Review follows submission of a time and extent application by Clariant...
Advertisement

Related Content

Clariant TEA extension
FDA To Review Piroctone Olamine For OTC Dandruff Monograph Status
FDA To Review Piroctone Olamine For OTC Dandruff Monograph Status
Advertisement
UsernamePublicRestriction

Register

RS012110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel